黄葵胶囊对慢性肾衰竭模型肾纤维化的影响

目的：本文拟探讨黄葵胶囊对慢性肾衰竭（chronic renal failure,CRF）肾纤维化的影响。方法：采用腺嘌呤制作大鼠慢性肾衰竭模型,本实验分为4组：正常组、模型组、黄葵胶囊组及苯那普利组,治疗4周后分别观察血清肌酐（Scr）、尿素氮（BUN）及血红蛋白（Hb）的改变,以及组织病理学改变。结果：在模型组中Scr及BUN水平明显高于正常组,其肾脏病理改变主要为小管间质纤维化;采用黄葵胶囊治疗后Scr及BUN水平明显降低,Hb改善,与模型组比较有统计学差异（P〈0.05）,且病理改变明显减轻。结论：黄葵胶囊可减轻CRF模型中肾纤维化程度。     

肾毒宁冲剂对慢性肾衰竭大鼠肾组织TGF-β1和CTGF的影响

目的：观察肾毒宁冲剂对5/6肾切除慢性肾衰竭（CRF）大鼠肾组织转化生长因子-β1（TGF-β1）、结缔组织生长因子（CTGF）的影响。方法：取雄性SD大鼠,通过Platt法5/6肾切除制作CRF模型,术后2周行大鼠断尾采血,测定血清肌酐（Scr）、尿素氮（BUN）值,根据Scr随机分为模型组、尿毒清组及肾毒宁组,并设正常组和假手术组。饲养或治疗8周后处死大鼠,测定血Scr、BUN、Hb、RBC,用Real-time PCR法测定肾组织内TGF-β1及CTGF的表达。结果：肾毒宁组血Scr、BUN、Hb、RBC与模型组相比有统计学差异（P〈0.01）。肾毒宁冲剂对肾组织内TGF-β1、CTGF表达有较强的抑制作用（P〈0.05和P〈0.01）,尿毒清冲剂作用次之,肾毒宁组与尿毒清组间无统计学差异。结论：肾毒宁冲剂通过抑制肾组织TGF-β1、CTGF的表达,降低血清Scr、BUN含量,从而起到延缓CRF肾功能的恶化,改善肾脏纤维化的作用。     

肾毒宁冲剂对慢性肾衰竭大鼠肾组织细胞外基质的影响

目的：观察肾毒宁冲剂对5/6肾切除慢性肾衰竭（CRF）大鼠肾组织细胞外基质（ECM）主要成分纤维连接蛋白（FN）、层黏连蛋白（LN）、Ⅲ型胶原（ColⅢ）的影响。方法：取雄性SD大鼠,通过Platt法5/6肾切除制作CRF模型,术后2周行大鼠断尾采血,测定血清肌酐（Scr）、血尿素氮（BUN）值,根据Scr随机分为模型组、尿毒清组及肾毒宁组,并设正常组和假手术组。饲养或治疗8周后处死大鼠,测定Scr、BUN、Hb、RBC、24h尿蛋白定量及肾组织内FN、LN和ColⅢ的表达。结果：肾毒宁组Scr、BUN、Hb、RBC、24h尿蛋白定量与模型组相比差异有统计学意义（P〈0.01）。肾毒宁冲剂对肾组织ECM主要成分FN、LN和ColⅢ表达有较强的抑制作用（P〈0.01）,尿毒清冲剂作用次之,肾毒宁组与尿毒清组间差异无统计学意义。结论：肾毒宁冲剂可显著改善肾功能,这可能与肾毒宁冲剂能抑制CRF大鼠肾组织FN、LN和ColⅢ表达有关。     

红细胞生成素对慢性肾衰竭大鼠肾小球内皮细胞功能的影响

目的 探讨红细胞生成素（EPO）对慢性肾衰竭（CRF）大鼠肾小球内皮细胞功能的影响。 方法 采用分阶段5/6肾切除术制备大鼠慢性肾衰竭动物模型。实验动物按数字随机法分为4组：假手术组（对照组）、慢性肾衰竭组（模型组）及EPO干预的两个剂量组（小剂量组EPO用量30 U/kg,大剂量组EPO用量50 U/kg）。慢性肾衰竭大鼠皮下注射EPO 6周后处死。检测各组大鼠血肌酐（Scr）、血尿素氮（BUN）、尿蛋白、血红蛋白（Hb）和血压的变化,并观察肾组织病理改变。免疫组化法检测肾小球CD34、CD31表达;RT-PCR检测肾组织内皮素1（ET-1）、内皮细胞一氧化氮合酶（eNOS）和血管内皮细胞生长因子（VEGF） mRNA的表达。 结果 与模型组比较,EPO治疗能显著增加大鼠肾小球CD34、CD31的表达（均P < 0.05）;下调肾组织ET-1 mRNA的表达（P < 0.05）;上调肾组织eNOS和 VEGF mRNA的表达（均P < 0.05）。此外,EPO治疗还能使大鼠Scr、BUN、尿蛋白和血压水平显著降低（均P < 0.05）,Hb水平显著增高（P < 0.05）,肾组织病理损害明显减轻。 结论 EPO能减轻慢性肾衰竭大鼠肾脏的病理损害,改善肾功能。这种作用可能与其促进肾小球内皮细胞的修复和改善内皮功能有关。     

升清降浊胶囊对慢性肾衰竭大鼠保护机制的实验研究

目的:探讨升清降浊胶囊对腺嘌呤所致慢性肾衰竭大鼠的肾功能改善作用,以及对钙、磷、FGF-23及TGF-β1/Smads/BMP-7信号通路的影响。方法:72只SD雄性大鼠随机抽取62只用腺嘌呤灌胃造模28 d,另10只设为正常对照组正常饲养;造模成功后采用随机分组方法分为5组:模型组,升清降浊胶囊低、中、高浓度组(剂量0.09、0.18、0.36 g/ml)、肾衰宁胶囊组(剂量0.225 g/ml),每组各10只。造模完成后第3天,每天8:00am给药治疗,观察实验第8周大鼠一般情况、肾脏病理形态学、血清中Scr、BUN、钙、磷的变化,采用酶联免疫吸附法检测FGF-23水平;应用免疫组织化学法检测各组大鼠TGF-β1、Smad2、Smad6、BMP-7蛋白表达。结果:(1)与正常组比较,模型组血清中BUN、Scr、磷、FGF-23水平明显升高,差异有统计学意义(P0.05),血钙水平下降(P0.05);与模型组比较,各治疗组BUN、Scr、磷、FGF-23水平均有不同程度下降(P0.05或P0.01),以升清降浊胶囊高剂量组最为显著;血钙水平上升,高剂量组差异有统计学意义(P0.05)。(2)大鼠肾脏组织TGF-β1、Smad2、Smad6、BMP-7蛋白表达:与正常组比较,模型组TGF-β1、Smad2蛋白表达增高(P0.05);与模型组比较,各治疗组蛋白表达均有不同程度降低,以高剂量组最为显著(P0.05);Smad6、BMP-7蛋白表达与上述因子相反(P0.05)。结论:(1)升清降浊胶囊有效改善慢性肾衰竭大鼠的肾功能,降低血清中磷、FGF-23的水平,提高血钙含量,以高剂量组明显。(2)升清降浊胶囊对慢性肾衰竭大鼠有良好的保护作用,通过干预TGF-β1/Smads/BMP-7信号通路达到抑制肾间质纤维化作用。     

虫草制剂对延缓慢性肾衰竭进展的实验研究

目的：为观察中药治疗慢性肾衰竭(CRF)的疗效。方法：采用5／6肾切除大鼠CRF模型，对肾衰大鼠用中药治疗后的肾功能等血液生化指标及残余肾组织病理情况进行了检查。结果：发现中药可降低CRF大鼠的死亡率，降低血Scr和BUN水平，具有明显的延缓CRF进展的作用。在肾组织病理学改变上，中药能延缓肾小球硬化的进展。结论：中药能有效控制慢性肾衰竭的进展。     

益肾胶囊对糖尿病肾病大鼠肾组织TGF-β1及Smad7表达的影响

目的：探讨益肾胶囊对糖尿病肾病大鼠肾组织TGF-β1及Smad7表达的影响.方法：将32只雄性Wistar大鼠,随机分为对照组、糖尿病肾病模型组、氯沙坦治疗组、益肾胶囊治疗组,每组8只.治疗组给予氯沙坦钾（20 mg·kg-1·d-1）、益肾胶囊（625 mg· kg-1·d-1）灌胃8周.测定血糖、24 h尿蛋白定量、血肌酐（Scr）和尿素氮（BUN）,计算内生肌酐清除率（Ccr）;观察肾脏病理变化及肾组织中TGF-β1和Smad7蛋白的表达.结果：与对照组相比,糖尿病肾病模型组大鼠血糖、24h尿蛋白定量、Scr和BUN明显升高,Ccr显著降低;肾组织出现较明显的病理损伤;且肾组织TGF-β1表达显著上调,Smad7蛋白表达量明显减少.益肾胶囊治疗后,与糖尿病肾病模型组相比,24 h尿蛋白定量、Scr和BUN明显下降,Ccr显著上升;肾组织病理损伤程度减轻;此外,肾组织TGF-β1表达显著下调,Smad7蛋白表达量明显增加.结论：益肾胶囊可能通过调节TGF-β1/Smad的表达,从而对糖尿病肾病发挥肾脏保护作用.     

重组肝再生增强因子对5/6肾切除大鼠模型肾性贫血的影响

目的：探讨重组人肝再生增强因子（rhALR）对5/6肾切除所致慢性肾衰竭大鼠肾性贫血的影响。方法：将雄性SD大鼠随机分为假手术组、对照组及rhALR组。对照组及rhALR组大鼠行5/6肾切除,术后12周慢性肾衰竭大鼠模型成功,以rhALR对rhALR组大鼠进行治疗,用药1周,于用药结束后24 h比较各组大鼠血常规、血清尿素氮（BUN）、肌酐（Scr）、血清铁、血清促红细胞生成素（EPO）等各项指标。结果：rhALR能升高5/6肾切除肾衰竭大鼠血红蛋白（Hb）、红细胞计数（RBC）、红细胞压积（HCT）、EPO水平,降低肾衰竭大鼠血中Scr及BUN水平。与对照组相比差异有统计学意义。结论：rhALR可有效改善5/6肾切除所致慢性肾衰竭肾性贫血,升高血中Hb、RBC、HCT、EPO水平,并对肾功能有保护作用。     

百令胶囊对糖尿病肾病大鼠生化指标及肾组织病理学改变的影响

目的:观察百令胶囊对糖尿病肾病大鼠血压、血糖、24 h尿蛋白定量、肾功能及大鼠肾组织病理变化的作用.方法:24只大鼠随机分为对照组、模型组、治疗组,每组各8只.复制糖尿病肾病大鼠模型成功2 d后,治疗组每日灌胃百令胶囊(2.5 g/kg),模型组及对照组每日给予等量的饮用水,测定血糖及24 h尿蛋白定量;通过全自动生化分析仪检测血肌酐(Scr)、尿素氮(BUN),并计算内生肌酐清除率(Ccr);通过光镜观察肾脏病理变化.结果:给药12周后,模型组大鼠血糖、平均动脉压、24 h尿蛋白定量、Scr、BUN及左肾/体重均明显高于对照组大鼠,而Ccr低于对照组大鼠,均P＜0.05,且肾组织出现了较明显的病理损伤;经百令胶囊治疗后,大鼠平均动脉压、24 h尿蛋白定量、Scr、BUN及左肾/体重均明显减低,均P＜0.05,血糖减低,Ccr显著增高,P＜0.05,肾组织病理损伤明显减轻.结论:百令胶囊对糖尿病肾病大鼠具有肾保护作用.     

骨髓间充质干细胞移植对过度运动所致急性肾损伤的研究

目的：探讨外源性骨髓间充质干细胞（MSCs）移植对过度运动导致急性肾损伤的保护作用.方法：建立过度运动致大鼠急性肾损伤模型,随机分为对照组和移植组,于细胞移植后测定血尿素氮（BUN）和血肌酐（Scr）水平,免疫组化观察肾组织切片.结果：移植组大鼠BUN和Scr明显低于对照组（P＜0.05）,免疫组化显示移植组肾损伤病理损伤明显减轻.结论：MSCs移植可促进过度运动所致急性肾损伤的修复,改善肾功能.     

Attempts to induce immunological enhancement for kidney allografts in rhesus monkeys.

Various rhesus alloantisera were tested for their capacity to induce enhancement of kidney allograft survival in D locus-incompatible rhesus monkeys. Six experimental groups were investigated: 1, ten allografted monkeys remained untreated; 2, six recipients were treated with Imuran and prednisolone; 3, eight rhesus monkeys were treated with a polyspecific "anti-SD" serum; 4, four animals were given oligospecific antikidney serum; 5, four monkeys were treated with oligospecific antiblood serum; and 6, nine recipients were given anti-Ia-like sera plus immunosuppressive treatment with Imuran and prednisolone. It was found that neither treatment with Imuran and prednisolone nor the administration of any of the alloantisera had a substantial effect on kidney graft survival. However, there appeared to be a difference in renal function among experimental groups. At 6 days after grafting, the mean blood urea level in the group treated with Ia-like antisera was found to be significantly lower than those of all other groups. It is discussed that this favourable effect is attributable to treatment with anti-Ia-like sera and not to the additional factors (conventional immunosuppression and partial matching for Ia-like antigens) occurring in this experimental group.     

Long-term effect of urokinase therapy in IgA nephropathy

Effects of urokinase (UK) therapy in patients with moderate to advanced degrees of IgA nephropathy (IgAN) were examined. Twenty-seven patients were treated by "two weeks" UK administration, 14 patients were treated by "consecutive" UK administration and 16 patients were treated by antiplatelet drugs. There were marked improvements in urinary protein concentration, serum creatinine and blood urea nitrogen after UK therapy, especially in patients treated by "consecutive" UK administration which was performed by "single shot" UK injection. Clinical prognosis was favorable in patients treated by UK administration compared with those given antiplatelet treatment. It was concluded that "consecutive" UK administration might be useful for treatment of IgAN with moderate to advanced renal injuries.     

Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial

Background

Dyslipidemia is a risk factor for the progression of chronic kidney disease (CKD). While conventional lipid lowering therapy provides a benefit to CKD management, the effect of statins on eGFR remains unclear.

Methods

A prospective, multi-center, open-labeled, randomized trial. Total of 349 CKD patients with hyperlipidemia were randomized into 2 groups, and followed for 2 years. Group A included patients who were treated with atorvastatin. Group C were treated with conventional lipid lowering drugs other than statin. Primary endpoint was changes in eGFR. Secondary endpoints included changes in urinary albumin excretion, serum LDL-C, serum triglyceride, cardio-vascular events and all-cause mortality.

Results

As the primary endpoint, eGFR decreased by 2.3 ml/min/1.73 m² in Group A and by 2.6 ml/min/1.73 m² in Group C, indicating that there was no difference in change of eGFR between the two groups. As secondary endpoints, atorvastatin succeeded to reduce serum LDL-C level significantly and rapidly, but conventional therapy did not. In fact, mean LDL-C level did not reach the target level of 100 mg/dl in Group C. Serum triglyceride was lowered only by atorvastatin, but not conventional drugs. The number of cardiovascular events and all-cause mortality did not differ between in two groups.

Conclusion

The ASUCA (Assessment of Clinical Usefulness in CKD Patients with Atorvastatin) trial demonstrated that atorvastatin failed to exhibit reno-protections compared to conventional therapy in Japanese patients with dyslipidemia and CKD. It would be due in part to the ability of atorvastatin to more potently reduce serum LDL and triglycerides compared to conventional therapy.

     

厄贝沙坦治疗慢性肾功能不全合并高尿酸血症的疗效观察

目的探讨厄贝沙坦治疗慢性肾功能不全合并高尿酸血症的疗效。方法将84例慢性肾功能不全合并高尿酸血症的患者随机分为A、B、C3组，分别给予厄贝沙坦、厄贝沙坦双倍剂量和非血管紧张素受体拮抗剂类降压药治疗，凡影响尿酸代谢的药物均不使用。于治疗前和治疗后15、30、45d检测血尿酸、血压水平及。肾功能。结果A、B两组患者治疗后血尿酸值明显下降，有显著性差异（P〈0．01），而C组患者治疗前、后血尿酸水平无显著性差异（P〉0．05）。3组患者血压水平均控制在135／85mmHg以下，且血尿酸下降水平与血肌酐的下降水平无相关关系。结论厄贝沙坦降压保护肾功能同时能明显的降低血尿酸水平。     

EFFECT OF LITHIUM ON CYCLOSPORIN INDUCED NEPHROTOXICITY IN RATS

Psychoactive drugs provide essential intervention in the care of transplant recipients, yet little is known of their interaction with immunosuppressants such as cyclosporin (CSA). Lithium (Li) is an invaluable drug for the treatment of manic disorders in organ transplant patients. As both these drugs are known to produce renal toxicity, the concomitant use of CSA and Li may be potentially harmful. The present study was undertaken to investigate the effect of CSA and Li chloride individually and in combination on renal structure and function of rats. Male Sprague-Dawley rats were divided into the following eight groups of seven animals each: group 1, control (vehicle only); group 2, Li (2mEq/kg i.p.) alone; group 3, CSA 12.5 mg/kg (subcutaneous); group 4, CSA 25 mg/kg; group 5, CSA 50 mg/kg; group 6, CSA 12.5 mg/kg + Li; group 7, CSA 25 mg/kg + Li; and group 8, CSA 50 mg/kg + Li. The drugs were given once a day for seven days; Li being administered 30 min before CSA. Twenty four hours after the last dose of drugs the animals were sacrificed and blood samples were analyzed for blood urea nitrogen (BUN), serum creatinine (SCr), CSA and Li levels. The left kidney was analyzed for malondialdehyde (MDA) and conjugated dienes (CD) levels and right kidney was used for histopathological studies. Our results showed that Li alone did not produce any significant renal toxicity, whereas CSA dose dependently caused structural and functional changes in kidneys. However, significantly higher structural and functional impairment was observed in the animals treated with Li plus CSA as compared to CSA alone treated animals. Several fold increase in blood Li level was also noticed in the rats concomitantly treated with CSA and Li. A significant increase in MDA and CD in the rats treated with CSA plus Li suggests the role of oxidative stress in drug induced nephrotoxicity. These findings clearly demonstrate that even non toxic doses of Li may significantly exacerbate CSA induced nephrotoxicity in rats. The enhanced nephrotoxicity following concomitant use of these drugs may be attributed to significant increase in the bioavailability of Li and enhanced oxidative stress. Further clinical studies are warranted to investigate the interaction of these nephrotoxic drugs in human subjects.     

Effect of lithium on cyclosporin induced nephrotoxicity in rats

Psychoactive drugs provide essential intervention in the care of transplant recipients, yet little is known of their interaction with immunosuppressants such as cyclosporin (CSA). Lithium (Li) is an invaluable drug for the treatment of manic disorders in organ transplant patients. As both these drugs are known to produce renal toxicity, the concomitant use of CSA and Li may be potentially harmful. The present study was undertaken to investigate the effect of CSA and Li chloride individually and in combination on renal structure and function of rats. Male Sprague-Dawley rats were divided into the following eight groups of seven animals each: group I, control (vehicle only); group 2, Li (2 mEq/ kg i.p.) alone; group 3, CSA 12.5 mg/kg (subcutaneous); group 4, CSA 25 mg/kg; group 5, CSA 50 mg/kg; group 6, CSA 12.5 mg/kg + Li; group 7, CSA 25 mg/kg + Li; and group 8, CSA 50 mg/kg + Li. The drugs were given once a day for seven days; Li being administered 30 min before CSA. Twenty four hours after the last dose of drugs the animals were sacrificed and blood samples were analyzed for blood urea nitrogen (BUN), serum creatinine (SCr), CSA and Li levels. The left kidney was analyzed for malondialdehyde (MDA) and conjugated dienes (CD) levels and right kidney was used for histopathological studies. Our results showed that Li alone did not produce any significant renal toxicity, whereas CSA dose dependently caused structural and functional changes in kidneys. However, significantly higher structural and functional impairment was observed in the animals treated with Li plus CSA as compared to CSA alone treated animals. Several fold increase in blood Li level was also noticed in the rats concomitantly treated with CSA and Li. A significant increase in MDA and CD in the rats treated with CSA plus Li suggests the role of oxidative stress in drug induced nephrotoxicity. These findings clearly demonstrate that even non toxic doses of Li may significantly exacerbate CSA induced nephrotoxicity in rats. The enhanced nephrotoxicity following concomitant use of these drugs may be attributed to significant increase in the bioavailability of Li and enhanced oxidative stress. Further clinical studies are warranted to investigate the interaction of these nephrotoxic drugs in human subjects.     

腰痛康对模拟神经根炎血液流变学及血清NO浓度的影响

目的研究活血化瘀中药制剂腰痛康治疗血瘀型腰痛的作用机理。方法把40只成年白兔制成模拟神经根炎，随机分为空白对照组、腰痛康煎剂组、腰痛康膏剂组、阳性对照药腰痛宁组。给药的3个组自造模术后第2天开始每天灌胃给药。于给药第7天和第15天采血作血液流变学检查，于给药第10天采血作血清NO浓度检测。结果与空白对照组相比，腰痛康煎剂组和膏剂组给药7天时其血浆粘度、纤维蛋白原、血沉有不同程度的降S氏；给药15天时其全血粘度、红细胞聚积有不同程度的降低；给药10天时其血清NO显著降低。结论腰痛康可以改善血液的粘浓状态，降低血清NO浓度，促使神经根炎症的消除和组织修复，从而达到止痛的效果。     

The effects of long-term low-dose hormone replacement therapy on blood pressure and vasoactive factors in postmenopausal women

<正> Objective:To investigate the effects of long-term low-dose hormone replacement therapy(HRT)on blood pressure,the plasma renin activity(PRA),plasma angiotensin Ⅱ(AngⅡ)leveland serum nitric oxide(NO)concentration in postmenopausal women.Methods:A total of 140 postmenopausal women were selected from the medical staff of thePeking Union Medical College Hospital.Of these,63 subjects who had been treated with low-dose sex hormone for over 5(5-32)years were set up as HRT group,and 77 age-matched sub-jects who had never received HRT were designed as control group.The levels of serum estradiol(E_2),follicle stimulating hormone(FSH)and nitric oxide(NO),the concentration of plasma an-giotensin Ⅱ(AngⅡ),plasma rennin activity(PRA)and the blood pressure were evaluated inthese two groups.Results:The serum level of estradiol in HRT group was significantly higher than that in con-trol group(median,interquartile range;124.0 pmol/L,113.4 vs.78.2 pmol/L,121.8)(P<0.05)and systolic blood pressure in HRT groups was significantly lower than that in control group[(126.7±14.4)mmHg vs.(132.4+19.8)mmHg](P<0.05).Diastolic blood pressure[(79.7±7.9)mmHg vs.(79.6±10.4)mmHg],the serum level of FSH[(54.4±18.9)IU/L vs.(60.4±24.4)IU/L],the plasma level of PRA(median,interquartile range;0.14 pg/L/hr,0.11vs.0.12 pg/L/hr,0.10),AngⅡ(median,interquartile range;46.0,31.1 pg/ml vs.44.4,33.0pg/ml)and serum level of NO(median,interquartile range;63.8 μmol/L,58.9 vs.56.0 μmol/L,94.8)showed no significant difference between HRT and control groups(P>0.05).Conclusions:Long-term low-dose HRT decreased the systolic blood pressure,but showed noeffects on the diastolic blood pressure,plasma level of AngⅡ,PRA,and serum level of NO inpostmenopausal women.     

Auswirkungen der endovaskul?ren Therapie von Nierenarterienstenosen auf Blutdruck und Nierenfunktion

Background

A retrospective analysis of the long-term success rates of endoluminal therapy of renal artery stenosis in a university hospital was carried out.

Material and methods

Preinterventional and postinterventional data contained in the clinical records of all 104 patients who underwent percutaneous transluminal angioplasty (PTA, 25 patients) or stent PTA (79 patients) from 01 January 1994 to 31 December 2007, were documented using an electronically structured questionnaire and a time period classification. Subgroup analyses and statistical calculations were done using t-tests for joint random samples.

Results

At day 1 postintervention all patients showed a statistically significant decrease in mean systolic blood pressure (all patients: p=0.002, stent PTA group: p=0.023, PTA group: p=0.022). The significant decrease in mean systolic blood pressure persisted in years 1 and 2 postintervention (all patients: p=0.009 and 0.007, stent PTA group: p=0.039 and 0.015, respectively). Mean blood pressure values remained constant during the other time periods analyzed. In patients with a stent PTA carried out between 2001 and 2007 there was no significant reduction of prescribed antihypertonic drugs (p=0.023 and p=0.046, respectively). Mean serum creatinine concentrations decreased during years 1 and 2 postintervention and increased starting in year 3. In patients with elevated serum creatinine levels prior to the intervention the increase in mean serum creatinine level started in year 5.

Conclusions

Endoluminal therapy of arteriosclerotic renal artery stenosis delays further deterioration of renal function and stabilizes blood pressure as well as the number of prescribed antihypertonic drugs. This can be considered a response to treatment in view of the mostly chronic progressive course of the disease.     

腹股沟疝患者行腹腔镜无张力修补术后疼痛及血气指标的研究

目的探讨腹股沟疝患者行腹腔镜无张力修补术后疼痛及血气指标的变化情况。 方法以2017年2月至2019年5月在河北北方学院附属第一医院普外科就诊的60例腹股沟疝患者为研究对象。采用随机数表法将其分为对照组和对照组。其中，对照组27例，对照组33例。对照组采用开放式无张力修补术进行治疗，对照组采用腹腔镜无张力修补术进行治疗。记录2组围术期情况，术后6、24、72 h的疼痛评分；使用血气分析仪观察2组患者气腹前、气腹后20 min及放气后动脉血氧分压（PaO₂）、pH及动脉血二氧化碳分压（PaCO₂）的变化；检测2组术前及术后24、72 h血清炎症因子的含量；统计2组术后不良反应发生情况。计量资料以（ ±s）表示，用t检验作比较分析。不同时间测量指标用方差分析作比较。计数资料以率（%）表示，用χ²检验作比较分析。 结果对照组手术时间、住院时间均短于对照组，术中出血量低于对照组，差异有统计学意义（t=3.660，13.857，18.661；P<0.05）。与治疗前比，术后24、72 h，2组疼痛评分呈逐渐降低趋势，且对照组低于对照组，差异有统计学意义（t=3.660，19.351，16.096；P<0.05）。与气腹前比，气腹后20 min，2组pH、PaO₂水平均降低，PaCO₂水平均升高，且对照组pH、PaO₂水平均低于对照组，PaCO₂水平高于对照组，差异有统计学意义（F=4.545，28.441，59.922；P<0.05）。与术前比，术后24 h、72 h，2组血清C-反应蛋白、白介素-6水平均降低，且对照组低于对照组，差异有统计学意义（F=69.629，13.489，292.441，65.421；P<0.05）。对照组术后总不良反应率为6.06%，低于对照组的25.93%，差异有统计学意义（χ²=4.596；P<0.05）。 结论对腹股沟疝患者行腹腔镜无张力修补术治疗，可显著改善患者围手术期的情况及血气指标水平，并可抑制患者炎症反应，缓解疼痛。此外，该手术具有较高安全性，值得推广。